Trial Outcomes & Findings for Sickle Cell Disease (SCD) Bone Pain Study (NCT NCT05283148)
NCT ID: NCT05283148
Last Updated: 2025-08-24
Results Overview
Areal bone mineral density of the lumbar spine measured by dual-energy X-ray absorptiometry (DXA) scan and reported in grams per square centimeter.
ACTIVE_NOT_RECRUITING
NA
53 participants
Baseline
2025-08-24
Participant Flow
One hundred and twenty-eight unique adults (age 18 years and older) with SCD of any genotype seen in the Adult Sickle Cell clinic at UCD's Comprehensive Cancer Center between 2022-2023 were eligible to participate in the SCD Bone Pain study.
From this convenience sample of 128 SCD adults, 72 were approached to participate in the study, and 53 participants eventually enrolled in the SCD Bone Pain study
Participant milestones
| Measure |
SCD Bone Pain Study Cohort
The SCD Bone Pain study was a single-arm, prospective, observational cohort study of 53 adults with sickle cell disease (SCD) undergoing research DXA scans to assess bone mineral density, thoracolumbar morphometry for vertebral fracture analyses, and ASC-Me pain impact assessment.
Definitions:
Dual-energy X-ray absorptiometry (DXA) scan: Used to measure bone mineral density at the lumbar spine, total hip, forearm, and whole body
Vertebral fracture analysis (VFA): Obtained from thoracolumbar morphometry in DXA scanner, then grade presence and severity of vertebral compression fractures using spinal deformity index
Adult Sickle Cell Quality of Life Measurement System (ASCQ-Me) pain impact questionnaire: Calculate patient-reported total pain scores to determine the pain phenotype of each study participant
|
|---|---|
|
Overall Study
STARTED
|
53
|
|
Overall Study
COMPLETED
|
53
|
|
Overall Study
NOT COMPLETED
|
0
|
Reasons for withdrawal
Withdrawal data not reported
Baseline Characteristics
Sickle Cell Disease (SCD) Bone Pain Study
Baseline characteristics by cohort
| Measure |
SCD Bone Pain Study Cohort
n=53 Participants
Prospective cohort of 53 adults with sickle cell disease (SCD) to assess the following:
1. Bone mineral density (BMD) at the lumbar spine, left total hip, left forearm, and whole body, using a dual-energy X-ray absorptiometry (DXA) scan
2. Spinal deformity index (measure of presence and severity of vertebral fractures) using thoracolumbar morphometry obtained from the DXA scanner
3. Patient-reported pain impact score obtained from the Adult Sickle Cell Quality of Life Measurement System (ASCQ-Me) Pain impact questionnaire
|
|---|---|
|
Age, Continuous
|
36 Years
n=99 Participants
|
|
Sex: Female, Male
Female
|
34 Participants
n=99 Participants
|
|
Sex: Female, Male
Male
|
19 Participants
n=99 Participants
|
|
Ethnicity (NIH/OMB)
Hispanic or Latino
|
2 Participants
n=99 Participants
|
|
Ethnicity (NIH/OMB)
Not Hispanic or Latino
|
51 Participants
n=99 Participants
|
|
Ethnicity (NIH/OMB)
Unknown or Not Reported
|
0 Participants
n=99 Participants
|
|
Race (NIH/OMB)
American Indian or Alaska Native
|
0 Participants
n=99 Participants
|
|
Race (NIH/OMB)
Asian
|
0 Participants
n=99 Participants
|
|
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
|
0 Participants
n=99 Participants
|
|
Race (NIH/OMB)
Black or African American
|
50 Participants
n=99 Participants
|
|
Race (NIH/OMB)
White
|
1 Participants
n=99 Participants
|
|
Race (NIH/OMB)
More than one race
|
2 Participants
n=99 Participants
|
|
Race (NIH/OMB)
Unknown or Not Reported
|
0 Participants
n=99 Participants
|
|
Region of Enrollment
United States
|
53 Participants
n=99 Participants
|
|
Height
|
172 cm
n=99 Participants
|
|
Body mass index (BMI)
|
24.6 kg/m2
n=99 Participants
|
|
Sickle cell disease (SCD) genotype
Hb SS
|
30 Participants
n=99 Participants
|
|
Sickle cell disease (SCD) genotype
Hb SC
|
15 Participants
n=99 Participants
|
|
Sickle cell disease (SCD) genotype
Hb SB0
|
5 Participants
n=99 Participants
|
|
Sickle cell disease (SCD) genotype
Hb SB+
|
2 Participants
n=99 Participants
|
|
Sickle cell disease (SCD) genotype
Hb SD
|
1 Participants
n=99 Participants
|
|
Osteonecrosis
Yes
|
22 Participants
n=99 Participants
|
|
Osteonecrosis
No
|
31 Participants
n=99 Participants
|
PRIMARY outcome
Timeframe: BaselineAreal bone mineral density of the lumbar spine measured by dual-energy X-ray absorptiometry (DXA) scan and reported in grams per square centimeter.
Outcome measures
| Measure |
Group A
n=34 Participants
Female participants
|
Group B
n=19 Participants
Male Participants
|
|---|---|---|
|
Lumbar Spine Bone Mineral Density
|
0.97 g/cm2
Interval 0.62 to 1.31
|
1.0 g/cm2
Interval 0.72 to 1.67
|
PRIMARY outcome
Timeframe: BaselineNumber of standard deviations between measured lumbar spine bone mineral density (g/cm2) for each participant and mean lumbar spine bone mineral density (g/cm2) of the reference population. A Z-score of 0 represents the mean of the reference population. A negative Z-score means the measured bone mineral density values are lower (worse) the reference mean, while positive Z-scores mean they are above/higher. Bone mineral density Z-scores ≤ -2 indicates low bone density.
Outcome measures
| Measure |
Group A
n=34 Participants
Female participants
|
Group B
n=19 Participants
Male Participants
|
|---|---|---|
|
Lumbar Spine Bone Mineral Density-Z-scores
|
-1.35 Z-score
Interval -4.4 to 1.6
|
-1.60 Z-score
Interval -4.3 to 4.3
|
PRIMARY outcome
Timeframe: BaselineAreal bone mineral density of the total hip measured by dual-energy X-ray absorptiometry (DXA) scan and reported in grams per square centimeter.
Outcome measures
| Measure |
Group A
n=34 Participants
Female participants
|
Group B
n=19 Participants
Male Participants
|
|---|---|---|
|
Total Hip Bone Mineral Density (BMD)
|
0.90 g/cm2
Interval 0.66 to 1.34
|
1.03 g/cm2
Interval 0.67 to 1.76
|
PRIMARY outcome
Timeframe: At enrollmentNumber of standard deviations between measured total hip bone mineral density (g/cm2) for each participant and mean total hip bone mineral density (g/cm2) of the reference population. A Z-score of 0 represents the mean of the reference population. A negative Z-score means the measured bone mineral density values are lower (worse) the reference mean, while positive Z-scores mean they are above/higher. Bone mineral density Z-scores ≤ -2 indicates low bone density.
Outcome measures
| Measure |
Group A
n=34 Participants
Female participants
|
Group B
n=19 Participants
Male Participants
|
|---|---|---|
|
Total Hip Bone Mineral Density-Z-scores
|
-0.75 Z-score
Interval -2.3 to 2.0
|
-0.5 Z-score
Interval -2.7 to 3.5
|
PRIMARY outcome
Timeframe: BaselineAreal bone mineral density of the femoral neck measured by dual-energy X-ray absorptiometry (DXA) scan and reported in grams per square centimeter.
Outcome measures
| Measure |
Group A
n=34 Participants
Female participants
|
Group B
n=19 Participants
Male Participants
|
|---|---|---|
|
Femoral Neck Bone Mineral Density (BMD)
|
0.77 g/cm2
Interval 0.53 to 1.3
|
0.94 g/cm2
Interval 0.63 to 1.68
|
PRIMARY outcome
Timeframe: BaselineNumber of standard deviations between measured lumbar spine bone mineral density (g/cm2) for each participant and mean lumbar spine bone mineral density (g/cm2) of the reference population. A Z-score of 0 represents the mean of the reference population. A negative Z-score means the measured bone mineral density values are lower (worse) the reference mean, while positive Z-scores mean they are above/higher. Bone mineral density Z-scores ≤ -2 indicates low bone density.
Outcome measures
| Measure |
Group A
n=34 Participants
Female participants
|
Group B
n=19 Participants
Male Participants
|
|---|---|---|
|
Femoral Neck Bone Mineral Density Z-scores
|
-0.95 Z-score
Interval -2.7 to 2.4
|
-0.60 Z-score
Interval -2.3 to 4.0
|
PRIMARY outcome
Timeframe: BaselinePatient-reported outcome measure of pain impact in the preceding 7 days before bone density measurements. The Adult Sickle Cell Quality of Life Measurement System (ASCQ-Me) pain impact T-scores range from about 30-100. The ASCQ-Me pain impact T-score has standardized mean T-score of 50 and standard deviation of 10, which were derived from a reference population of ambulatory adult with sickle cell disease across the United States. ASCQ-Me pain impact T-scores less than 50 are lower/worse than the reference mean (more severe pain impact), while pain impact T-scores greater than 50 are above/better than the reference mean (less severe pain impact)
Outcome measures
| Measure |
Group A
n=23 Participants
Female participants
|
Group B
n=30 Participants
Male Participants
|
|---|---|---|
|
Adult Sickle Cell Quality of Life Measurement System (ASCQ-Me) Pain Impact T-scores
|
47.1 T-score
Interval 42.4 to 52.8
|
52.4 T-score
Interval 45.3 to 56.5
|
SECONDARY outcome
Timeframe: BaselinePopulation: Statistical analysis of spinal deformity index is ongoing. Complete results will be provided by February 2026.
The spinal deformity index (SDI) is a semi-quantitative measure of number and severity of vertebral fractures observed on lateral spine X-rays of the thoracolumbar spine. To calculate the SDI, vertebrae are assigned a score as follows: 0 (no fracture), 1 (mild fracture), 2 (moderate fracture), and 3 (severe fracture). The total SDI is the summation of all T12-L4 vertebrae measured on the lateral spine X-rays. Minimum SDI =0 and Maximum SDI=15. Higher scores mean increased (worse) fracture burden, lower scores mean decreased (less) fracture burden.
Outcome measures
| Measure |
Group A
n=23 Participants
Female participants
|
Group B
n=30 Participants
Male Participants
|
|---|---|---|
|
Spinal Deformity Index
|
2.00 score on a scale
Standard Deviation 2.71
|
3.13 score on a scale
Standard Deviation 3.98
|
Adverse Events
SCD Bone Pain Study Cohort
Serious adverse events
Adverse event data not reported
Other adverse events
Adverse event data not reported
Additional Information
Oyebimpe Adesina, MD, MS
University of California Davis Comprehensive Cancer Center
Results disclosure agreements
- Principal investigator is a sponsor employee
- Publication restrictions are in place